Educational information, not medical advice — ask your doctor or midwife.
Track Vitamin B3 with reminders and record whether it helped, in the app.
Vitamin B3 is a group of structurally related water-soluble compounds that serve as essential precursors to nicotinamide adenine dinucleotide (NAD+) and its reduced form NADH, coenzymes central to hundreds of oxidation-reduction reactions in human metabolism. The three principal forms with distinct biological roles are nicotinic acid (the lipid-modifying form), niacinamide/nicotinamide (the tissue-protective, anti-inflammatory form), and nicotinamide riboside (a newer, more bioavailable NAD+ precursor). Unlike most vitamins, nicotinic acid at pharmacological doses acts more like a drug, having been used as a lipid-modifying agent since the 1950s.
All B3 forms ultimately raise intracellular NAD+ levels, supporting mitochondrial energy production, DNA repair via PARP enzymes, and sirtuin-mediated gene regulation. Nicotinic acid additionally acts on GPR109A receptors in adipocytes to inhibit lipolysis, reducing free fatty acid flux to the liver and thereby lowering VLDL/triglyceride synthesis and raising HDL. Niacinamide, by contrast, does not bind GPR109A (and thus causes no flushing) but suppresses inflammatory cytokines and inhibits PARP overactivation, explaining its skin-protective and potentially neuroprotective effects.
Immediate-release nicotinic acid causes the most flushing but has the most cardiovascular outcome trial data. Extended-release niacin (Niaspan) reduces flushing but carries higher hepatotoxicity risk. Niacinamide capsules and topical serums (2–5%) are widely available OTC. Nicotinamide riboside is commercially available as Tru Niagen and similar brands, with multiple published human pharmacokinetic and safety trials.
Niacin's clinical history is unusually rich for a vitamin. The Coronary Drug Project (1975) was one of the first large trials to show that a nutrient—nicotinic acid—could reduce non-fatal myocardial infarction, and long-term follow-up data (Canner et al., 1986) suggested a mortality benefit. Pellagra, caused by severe B3 deficiency, was a major public health crisis in the early 20th-century American South, affecting hundreds of thousands; its dietary cause was identified by Joseph Goldberger in the 1910s–1920s.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.